Cyclosporine, an immunomodulating drug that inhibits T-cell activation and interleukin-2 production, has successfully treated refractory TTP; however, its use is rare now because it can also cause thrombotic microangiopathy, independent of TTP [10]. This evidence concerns the gene IL2 and thrombotic thrombocytopenic purpura.